Le migliori storie
-
2 anni fa
Improved RFS in Resected Melanoma with mRNA Vaccine/Pembrolizumab
targetedonc.com
-
2 anni fa
mRNA Vaccine/Pembrolizumab Significantly Improves RFS in Resected Melanoma
cancernetwork.com
-
2 anni fa
ESMO 2023: Efficacy of Niraparib and Abiraterone Acetate + Prednisone in Homologous Recombination Repair Gene-Altered Metastatic Castration-Resistant Prostate Cancer by Tissue And/or Plasma Assays in the MAGNITUDE Trial
urotoday.com
-
2 anni fa
Biontech developed a cancer vaccine! Reduced tumors in the brain by 30 percent
earthpressnews.com
-
2 anni fa
Phase 3 MARIPOSA-2 Study Shows RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy Given with or without Lazertinib Reduced Risk of Disease Progression or Death by 56 and 52 Percent Respectively in Patients with EGFR-Mutated Non-Small Cell Lung Cancer who Progressed on or after Osimertinib
jnj.com
-
2 anni fa
Landmark Phase 3 MARIPOSA Study Shows RYBREVANT® (amivantamab-vmjw) Plus Lazertinib Resulted in 30 Percent Reduction in Risk of Disease Progression or Death Compared to Osimertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer
jnj.com
-
2 anni fa
OSE Immunotherapeutics Announces First Clinical Results for BI 770371, a Novel Anti-SIRPα Monoclonal Antibody
finance.yahoo.com
-
2 anni fa
Phase III Trial: Datopotamab Deruxtecan Boosts Survival in Lung Cancer
miragenews.com
-
2 anni fa
Johnson & Johnson : Landmark Phase 3 MARIPOSA Study Shows RYBREVANT® (amivantamab-vmjw) Plus Lazertinib Resulted in 30 Percent Reduction in Risk of Disease Progression or Death Compared to Osimertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer
marketscreener.com